Literature DB >> 3670793

Correlation between steroid hormone receptors and prognostic factors in human breast cancer.

G P Barbi1, P Marroni, P Bruzzi, G Nicolò, M Paganuzzi, G B Ferrara.   

Abstract

Knowledge of the tumor content of estrogen (ER) and progesterone (PgR) receptors has proved to be of significant value in human breast cancer. Relative determinations were performed in 589 specimens in our laboratory. The positivity of ER and PgR is correlated with the patients' age at diagnosis, tumor size and relative grade. In particular, the significance of PgR versus ER status and the possible prognostic role of these receptors are investigated.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3670793     DOI： 10.1159/000226492

Source DB:  PubMed          Journal:  Oncology        ISSN： 0030-2414            Impact factor:   2.935


  4 in total

1.  A computer-aided diagnosis (CAD) scheme for pretreatment prediction of pathological response to neoadjuvant therapy using dynamic contrast-enhanced MRI texture features.

Authors:  Valentina Giannini; Simone Mazzetti; Agnese Marmo; Filippo Montemurro; Daniele Regge; Laura Martincich
Journal:  Br J Radiol       Date:  2017-07-14       Impact factor: 3.039

2.  Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set.

Authors:  Elizabeth Hope Cain; Ashirbani Saha; Michael R Harowicz; Jeffrey R Marks; P Kelly Marcom; Maciej A Mazurowski
Journal:  Breast Cancer Res Treat       Date:  2018-10-16       Impact factor: 4.872

3.  Inhibition of estrogen-responsive gene activation by the retinoid X receptor beta: evidence for multiple inhibitory pathways.

Authors:  J H Segars; M S Marks; S Hirschfeld; P H Driggers; E Martinez; J F Grippo; M Brown; W Wahli; K Ozato
Journal:  Mol Cell Biol       Date:  1993-04       Impact factor: 4.272

4.  Texture analysis on MR images helps predicting non-response to NAC in breast cancer.

Authors:  N Michoux; S Van den Broeck; L Lacoste; L Fellah; C Galant; M Berlière; I Leconte
Journal:  BMC Cancer       Date:  2015-08-05       Impact factor: 4.430
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.